COVID-19相关肺曲霉病的危险因素:系统评价与Meta分析
该系统评价与Meta分析检索5个数据库,纳入27篇病例对照和队列研究、共6848例COVID-19成人患者,其中1324例(19.3%)诊断为CAPA,CAPA诊断率范围为2.5%(566例中14例)至47.2%(123例中58例)。识别出8个CAPA危险因素:慢性肝病(OR 2.70)、血液恶性肿瘤(OR 2.47)、COPD(OR 2.00)、脑血管病(OR 1.31)、有创机械通气(OR 2.83)、肾脏替代治疗(OR 2.26)、IL-6抑制剂治疗(OR 2.88)、糖皮质激素治疗(OR 1.88)。CAPA患者年龄更大、机械通气时间更长;事后分析显示CAPA患者全因病死率更高(OR 2.65)。作者认为这些危险因素最终可能通过靶向抗真菌预防来干预。
要点
- CAPA患者全因病死率高于无CAPA者(20项研究;OR 2.65 [2.04-3.45],p<0.0001;I²=51%)。
- 有创机械通气(OR 2.83 [1.88-4.24],p<0.0001;I²=69%)和肾脏替代治疗(OR 2.26 [1.76-2.90],p<0.0001;I²=14%)与CAPA相关。
- COVID-19治疗中使用IL-6抑制剂(OR 2.88 [1.52-5.43],p=0.001;I²=89%)或糖皮质激素(OR 1.88 [1.28-2.77],p=0.001;I²=66%)与CAPA相关。
- 慢性肝病(OR 2.70 [1.21-6.04],p=0.02;I²=53%)、血液恶性肿瘤(OR 2.47 [1.27-4.83],p=0.008;I²=50%)、COPD(OR 2.00 [1.42-2.83],p<0.0001;I²=26%)、脑血管病(OR 1.31 [1.01-1.71],p=0.05;I²=46%)与CAPA相关。
- CAPA患者平均年龄66.6岁(SD 3.6)vs 无CAPA者63.5岁(5.3),平均差2.90(1.48-4.33),p<0.0001;机械通气时间19.3天(8.9)vs 13.5天(6.8),平均差5.53天(1.30-9.77),p=0.01。
适用人群与场景
- 成人(年龄>18岁)COVID-19患者,研究需描述至少6例CAPA并评估CAPA危险因素。
- 仅纳入有COVID-19阳性且无曲霉病对照人群的病例对照研究和队列研究。
- 检索时限为2019年12月1日至2023年7月27日发表的文献。
研究设计与关键结果
- 系统评价与Meta分析:检索5个数据库(Ovid MEDLINE、Ovid Embase、Cochrane系统评价数据库、Cochrane对照试验中心注册库、WHO COVID-19数据库),最终纳入27篇文章、6848例COVID-19患者,其中1324例(19.3%)诊断为CAPA;CAPA诊断率范围为2.5%(566例中14例)至47.2%(123例中58例)。
- 8个CAPA危险因素:慢性肝病OR 2.70(95%CI 1.21-6.04),p=0.02,I²=53%;血液恶性肿瘤OR 2.47(1.27-4.83),p=0.008,I²=50%;COPD OR 2.00(1.42-2.83),p<0.0001,I²=26%;脑血管病OR 1.31(1.01-1.71),p=0.05,I²=46%。
- 有创机械通气OR 2.83(95%CI 1.88-4.24),p<0.0001,I²=69%;肾脏替代治疗OR 2.26(1.76-2.90),p<0.0001,I²=14%;IL-6抑制剂治疗OR 2.88(1.52-5.43),p=0.001,I²=89%;糖皮质激素治疗OR 1.88(1.28-2.77),p=0.001,I²=66%。
- CAPA患者平均年龄66.6岁(SD 3.6)vs 无CAPA者63.5岁(5.3),平均差2.90(1.48-4.33),p<0.0001,I²=86%。
- CAPA患者机械通气时间(7项研究)平均19.3天(SD 8.9)vs 无CAPA者13.5天(6.8),平均差5.53天(1.30-9.77),p=0.01,I²=88%。
- 事后分析:CAPA患者全因病死率高于无CAPA者(20项研究;OR 2.65 [2.04-3.45],p<0.0001;I²=51%)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入病例对照研究和队列研究;采用随机效应模型,二分类变量用Mantel-Haenszel法,连续变量用逆方差法;用漏斗图评估发表偏倚。
- 研究注册于PROSPERO,CRD42022334405。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:识别出的CAPA危险因素最终可能通过对重症COVID-19患者进行靶向抗真菌预防来干预。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: COVID-19-associated pulmonary aspergillosis (CAPA) has been reported to be an emerging and potentially fatal complication of severe COVID-19. However, risk factors for CAPA have not been systematically addressed to date.
METHODS: In this systematic review and meta-analysis to identify factors associated with CAPA, we comprehensively searched five medical databases: Ovid MEDLINE; Ovid Embase; the Cochrane Database of Systematic Reviews; the Cochrane Central Register of Controlled Trials; and the WHO COVID-19 Database. All case-control and cohort studies in adults (aged >18 years) that described at least six cases of CAPA and evaluated any risk factors for CAPA, published from Dec 1, 2019, to July 27, 2023, were screened and assessed for inclusion. Only studies with a control population of COVID-19-positive individuals without aspergillosis were included. Two reviewers independently screened search results and extracted outcome data as summary estimates from eligible studies. The primary outcome was to identify the factors associated with CAPA. Meta-analysis was done with random-effects models, with use of the Mantel-Haenszel method to assess dichotomous outcomes as potential risk factors, or the inverse variance method to assess continuous variables for potential association with CAPA. Publication bias was assessed with funnel plots for factors associated with CAPA. The study is registered with PROSPERO, CRD42022334405.
FINDINGS: Of 3561 records identified, 27 articles were included in the meta-analysis. 6848 patients with COVID-19 were included, of whom 1324 (19·3%) were diagnosed with CAPA. Diagnosis rates of CAPA ranged from 2·5% (14 of 566 patients) to 47·2% (58 of 123). We identified eight risk factors for CAPA. These factors included pre-existing comorbidities of chronic liver disease (odds ratio [OR] 2·70 [95% CI 1·21-6·04], p=0·02; I2=53%), haematological malignancies (OR 2·47 [1·27-4·83], p=0·008; I2=50%), chronic obstructive pulmonary disease (OR 2·00 [1·42-2·83], p<0·0001; I2=26%), and cerebrovascular disease (OR 1·31 [1·01-1·71], p=0·05; I2=46%). Use of invasive mechanical ventilation (OR 2·83; 95% CI 1·88-4·24; p<0·0001; I2=69%), use of renal replacement therapy (OR 2·26 [1·76-2·90], p<0·0001; I2=14%), treatment of COVID-19 with interleukin-6 inhibitors (OR 2·88 [1·52-5·43], p=0·001; I2=89%), and treatment of COVID-19 with corticosteroids (OR 1·88 [1·28-2·77], p=0·001; I2=66%) were also associated with CAPA. Patients with CAPA were typically older than those without CAPA (mean age 66·6 years [SD 3·6] vs 63·5 years [5·3]; mean difference 2·90 [1·48-4·33], p<0·0001; I2=86%). The duration of mechanical ventilation in patients with CAPA was longer than in those without CAPA (n=7 studies; mean duration 19·3 days [8·9] vs 13·5 days [6·8]; mean difference 5·53 days [1·30-9·77], p=0·01; I2=88%). In post-hoc analysis, patients with CAPA had higher all-cause mortality than those without CAPA (n=20 studies; OR 2·65 [2·04-3·45], p<0·0001; I2=51%).
INTERPRETATION: The identified risk factors for CAPA could eventually be addressed with targeted antifungal prophylaxis in patients with severe COVID-19.
参考来源
- Gioia F, Walti LN, Orchanian-Cheff A, et al. Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Lancet Respir Med. 2024. PMID: 38185135. doi:10.1016/S2213-2600(23)00408-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。